SEC For	rm 4																
FORM 4 UNITED S				ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									0	OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					TOF CHANGES IN BENEFICIAL OWNERSHIP								OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
				0	r Sectio	on 30(h) (	of the	Investment C	Company Act	of 1940							
1. Name and Address of Reporting Person*       Kunkel Lori Anne					2. Issuer Name <b>and</b> Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ ORIC ]							eck all applie X Directo	cable) or	10% Own			
(Last) (First) (Middle) C/O ORIC PHARMACEUTICALS, INC. 240 EAST GRAND AVE., 2ND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 06/16/2021							Officer (give title Other (specify below) below)					
(Street) SOUTH SAN FRANCISCO				_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																	
Table I - Non-Deriva   1. Title of Security (Instr. 3)   2. Transa   Date (Month/D)					n 2 E ear) i	Curities 2A. Deem Execution f any Month/Da	ed Date	, 3. Transacti Code (Ins	Transaction Disposed Of (D) (I Code (Instr. 5)		ed (A) or	5. Amou Securitie Beneficia	nt of ( s   ally ( following (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(Instr. 4)		
		7	Fable II - Deriv (e.g.,					uired, Dis s, options,				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$19.03	06/16/2021		A		16,625		(1)	06/15/2031	Common Stock	16,625	\$0.00	16,625	D			

## Explanation of Responses:

1. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant.

## **Remarks:**

Exhibit 24 - Power of Attorney

<u>/s/ Dominic Piscitelli, attorney-</u> <u>in-fact</u> <u>06/17/2021</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Oric Pharmaceuticals, Inc. (the "Company"), hereby constitutes and appoints Jacob Chacko and Dominic Piscitelli, and Christian Kuhlen, and each of them, as the undersigned's true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

2. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

3. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of April, 2021.

Signature: /s/ Lori A. Kunkel

Print Name: Lori A. Kunkel